JP2017524689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524689A5 JP2017524689A5 JP2017500864A JP2017500864A JP2017524689A5 JP 2017524689 A5 JP2017524689 A5 JP 2017524689A5 JP 2017500864 A JP2017500864 A JP 2017500864A JP 2017500864 A JP2017500864 A JP 2017500864A JP 2017524689 A5 JP2017524689 A5 JP 2017524689A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- snap25
- bont
- seq
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108030001720 Bontoxilysin Proteins 0.000 claims 8
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 claims 6
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 claims 6
- 230000002255 enzymatic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021379P | 2014-07-07 | 2014-07-07 | |
| US62/021,379 | 2014-07-07 | ||
| US201562158900P | 2015-05-08 | 2015-05-08 | |
| US62/158,900 | 2015-05-08 | ||
| US201562163829P | 2015-05-19 | 2015-05-19 | |
| US62/163,829 | 2015-05-19 | ||
| PCT/US2015/039372 WO2016007508A1 (en) | 2014-07-07 | 2015-07-07 | Method of detecting cleaved snap25 in tissue samples |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524689A JP2017524689A (ja) | 2017-08-31 |
| JP2017524689A5 true JP2017524689A5 (enExample) | 2018-08-16 |
| JP6630717B2 JP6630717B2 (ja) | 2020-01-15 |
Family
ID=55016834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500864A Expired - Fee Related JP6630717B2 (ja) | 2014-07-07 | 2015-07-07 | 組織試料における切断ｓｎａｐ２５の検出方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10527620B2 (enExample) |
| EP (2) | EP3567055A1 (enExample) |
| JP (1) | JP6630717B2 (enExample) |
| KR (1) | KR20170026624A (enExample) |
| CN (1) | CN107001451A (enExample) |
| CA (1) | CA2954504A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101609894B1 (ko) * | 2008-03-14 | 2016-04-08 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| KR101983216B1 (ko) * | 2018-11-29 | 2019-05-29 | 주식회사 에이비바이오 | 보툴리눔 독소 활성을 결정하기 위한 항체, 및 이를 이용한 활성 측정방법 |
| EP3660509B1 (en) | 2018-11-29 | 2022-03-09 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
| EP4204566A1 (en) | 2020-08-28 | 2023-07-05 | Galderma Holding SA | Novel x-aptamers for the use in detection of snap25 |
| CN119044508B (zh) * | 2024-10-31 | 2025-01-28 | 兰州生物技术开发有限公司 | 检测肉毒毒素活性或突触体相关蛋白的试剂盒及检测方法 |
| CN119044510B (zh) * | 2024-10-31 | 2025-01-28 | 兰州生物技术开发有限公司 | 一种测定肉毒毒素活性或snap25的试剂盒、抗体及方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5962637A (en) | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US20040219619A1 (en) | 2000-07-21 | 2004-11-04 | Ester Fernandez-Salas | Methods of identifying compounds that alter toxin persistence and/or protease activity |
| WO2003011902A1 (en) * | 2001-07-27 | 2003-02-13 | Kenton S.R.L. | Identification of specific tumour antigens by selection of cdna libraries with sera |
| US7208285B2 (en) | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| US7183066B2 (en) | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
| ATE533853T1 (de) | 2004-02-24 | 2011-12-15 | Allergan Inc | Botulinumtoxin-screening-assays |
| US7399607B2 (en) | 2004-09-22 | 2008-07-15 | Allergan, Inc. | Fluorescence polarization assays for determining clostridial toxin activity |
| WO2006042149A2 (en) | 2004-10-06 | 2006-04-20 | Allergan, Inc. | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
| DK1869459T3 (da) | 2005-04-05 | 2010-09-27 | Allergan Inc | Lipofil farve-baserede assays for clostridial-toksin-aktivitet |
| US20100227868A1 (en) | 2007-09-20 | 2010-09-09 | Johnson Brent A | Treatment methods with brimonidine |
| KR101604515B1 (ko) * | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| KR101609894B1 (ko) | 2008-03-14 | 2016-04-08 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| NZ594702A (en) | 2009-03-13 | 2013-05-31 | Allergan Inc | The SiMA cell line used for immuno-based or gene expression Botulinum Serotype A activity assays |
| JP5826635B2 (ja) * | 2009-03-13 | 2015-12-02 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 免疫系調節エンドペプチターゼ活性アッセイ |
| AU2010292532A1 (en) * | 2009-08-25 | 2012-04-05 | Berg Llc | Methods for treatment of a sarcoma using an epimetabolic shifter (Coenzyme Q10) |
| WO2015024503A1 (en) * | 2013-08-21 | 2015-02-26 | The Hong Kong Polytechnic University | Engineering clostridia neurotoxins with elevated catalytic activity |
-
2015
- 2015-07-07 CN CN201580042335.2A patent/CN107001451A/zh active Pending
- 2015-07-07 CA CA2954504A patent/CA2954504A1/en not_active Abandoned
- 2015-07-07 US US14/792,795 patent/US10527620B2/en not_active Expired - Fee Related
- 2015-07-07 KR KR1020177003275A patent/KR20170026624A/ko not_active Ceased
- 2015-07-07 JP JP2017500864A patent/JP6630717B2/ja not_active Expired - Fee Related
- 2015-07-07 EP EP19178110.3A patent/EP3567055A1/en not_active Withdrawn
- 2015-07-07 EP EP15739728.2A patent/EP3166971B1/en active Active
-
2019
- 2019-06-14 US US16/441,472 patent/US20190317095A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524689A5 (enExample) | ||
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| ES2641294T3 (es) | Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer | |
| UA102247C2 (ru) | Иммунологические анализы активности ботулинического токсина серотипа а | |
| JP2013060443A5 (enExample) | ||
| JP2014061000A5 (enExample) | ||
| AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| BR112014020213A2 (pt) | biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope | |
| UY33786A (es) | Proteínas de unión al TNF-a(alfa) | |
| BRPI1007867B8 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
| EA202090277A2 (ru) | Применение размера фрагмента бесклеточной днк для определения вариаций числа копий | |
| BR112013023540A2 (pt) | anticorpo, kit e método para a determinação de peptídeos amilóides | |
| EA201290629A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| CL2012001980A1 (es) | Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44. | |
| BR112013008602A2 (pt) | dispositivo imunocromatográfico, método para a determinação de um carreador gênico, método para o diagnóstico, dispositivo para ensaio imunológico, método para a detecção e determinação da presença de uma proteína e kit | |
| BR112016023238A2 (pt) | processos de tratamento seletivo de asma usando antagonistas de il-13 | |
| EA201590024A1 (ru) | Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток | |
| MX2015012825A (es) | Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc. | |
| MX2020010387A (es) | Metodos para detectar y cuantificar fgf21. | |
| CA2839777C (en) | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease | |
| JP2012073260A5 (enExample) | ||
| RU2016107954A (ru) | Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии | |
| BR112013007329A2 (pt) | método para diagnostificar o estado de doença de lyme em um mamífero, e, composição | |
| EA201990730A1 (ru) | Рнк-биомаркеры для наследственного ангионевротического отека |